Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03027557 · OUTCOME

Percent Change From Baseline in P-fibroblast Growth Factor 23 (FGF23).

Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet. · Source last updated 2021-05-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
% change
Interval / dispersion
Inter-Quartile Range
Time frame
Change from baseline at 48 weeks reported.

What was measured

P-FGF23 , change from baseline at 48 weeks.

Analysis population: One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final blood-sampling.

Groups in this outcome

Combined Treatment.

15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.

Denosumab Monotherapy

16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.

Placebo

15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Combined Treatment.14
Denosumab Monotherapy16
Placebo15

Reported measurements

Source class 1
Values in % change · Interval/dispersion: Inter-Quartile Range
GroupValueSpreadLowerUpperComment
Combined Treatment.35.8Not reported0.052.9Not reported
Denosumab Monotherapy20.4Not reported-13.658.2Not reported
Placebo28.0Not reported-25.964.7Not reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. group Ids
    1. OG000
    2. OG001
    3. OG002
    non Inferiority Type
    SUPERIORITY
    p Value
    = 0.85
    statistical Method
    ANOVA
Complete source fields
analyses
  1. group Ids
    1. OG000
    2. OG001
    3. OG002
    non Inferiority Type
    SUPERIORITY
    p Value
    = 0.85
    statistical Method
    ANOVA
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.0
        upper Limit
        52.9
        value
        35.8
      2. group Id
        OG001
        lower Limit
        -13.6
        upper Limit
        58.2
        value
        20.4
      3. group Id
        OG002
        lower Limit
        -25.9
        upper Limit
        64.7
        value
        28.0
denoms
  1. counts
    1. group Id
      OG000
      value
      14
    2. group Id
      OG001
      value
      16
    3. group Id
      OG002
      value
      15
    units
    Participants
description
P-FGF23 , change from baseline at 48 weeks.
dispersion Type
Inter-Quartile Range
groups
  1. description
    15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.
    id
    OG000
    title
    Combined Treatment.
  2. description
    16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.
    id
    OG001
    title
    Denosumab Monotherapy
  3. description
    15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.
    id
    OG002
    title
    Placebo
param Type
MEDIAN
population Description
One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final blood-sampling.
reporting Status
POSTED
time Frame
Change from baseline at 48 weeks reported.
title
Percent Change From Baseline in P-fibroblast Growth Factor 23 (FGF23).
type
SECONDARY
unit Of Measure
% change

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice